ProMIS Neurosciences Revenue and Competitors

ProMIS™ Neurosciences, Inc. (TSE: PMN, https://ca.finance.yahoo.com/q/bc?s=PMN.TO), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Several neurodegenerative diseases exhibit protein misfolding, such as AD, ALS, and Parkinson’s disease (PD). Recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. The company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (A?) and Tau in Alzheimer’s disease. The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the U. of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center. For over two decades, Dr. Cashman has been among the leaders in the field of misfolded proteins (over 300 publications,10,000 citations and 45 patent applications), and is a leading researcher of strain specific protein misfolding. The company’s patent estate consists of eight patent families issued or pending. ProMIS™ Neurosciences, Inc. uses its computational discovery platform, ProMIS™, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS™ Neurosciences, Inc. owns exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.